Rate My Professor Barry Hock

Hock's research interests center on myeloid-derived suppressor cells in cancer patients, mechanisms of immunosuppression by leukaemic cells, the tumor microenvironment, cancer immunotherapy, exercise effects on tumor growth and perfusion, the microbiome in colorectal carcinogenesis, and anti-drug antibodies impacting therapeutic monoclonals. His contributions include investigations into rheumatoid factors' effects on PD-1/PD-L1 inhibitors, innate priming of tumor-associated macrophages, and microbiome-molecular pathway links in colorectal cancer. Key publications feature 'Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1' (2025, Cancer Immunology, Immunotherapy), 'The role of innate priming in modifying tumor-associated macrophage phenotype' (2024, Frontiers in Bioscience - Landmark), 'Functional links between the microbiome and the molecular pathways of colorectal carcinogenesis' (2024, Cancer & Metastasis Reviews), 'Evaluation of the homogenous mobility shift assay for infliximab and adalimumab anti-drug antibody detection' (2024, Therapeutic Drug Monitoring), and 'Effect of post-implant exercise on tumour growth rate, perfusion and hypoxia in mice' (2020). With approximately 2,300 citations from 86 publications, his work significantly influences immunology and oncology.